Ra Medical Systems, Inc. (NYSE:
RMED) Elias Kassab, MD, presented his successful
experience using the DABRA laser system. “We have
found that DABRA is successful in treating
challenging lesions including long and severely
calcified lesions, both above and below the knee.” The
presentation was delivered on Wednesday, May 29,
2019, at the annual New Cardiovascular
Horizons (NCVH) conference in New Orleans.
Dr. Kassab, FACC, FSCAI, FACP. FASA, RPVI, FAHA,
FSVM, President & CEO of Michigan Outpatient Vascular
Institute, Dearborn, Michigan, continued, “The device has
an innate tendency to stay intraluminal in all vessels, is
versatile as a single debulking device, is easy to use and is
cost-effective. In our experience, DABRA has a very low
complication rate and we have not seen any angiographic or clinical
evidence of distal embolization.”
Dr. Kassab and Ashok Kondur, MD, recently reported that DABRA
achieved a 98% lesion success rate in a 52-patient, single-center
study that was summarized in the 2019 LINC Review. “Although
these findings are from just 52 patients, they are very promising
and strengthen the case for more extensive study of DABRA,” said
Dr. Kassab.
DABRA (Destruction of Arteriosclerotic Blockages by laser
Radiation Ablation) is a novel, minimally invasive excimer laser
system that non-thermally and photochemically ablates channels in
vascular blockages. The technology reduces all plaque types into
their fundamental chemistry, such as proteins, lipids, and other
chemical compounds, eliminating blockages by dissolving them
without generating potentially harmful particulates. Unlike many
mechanical, acoustic, or thermal treatments for peripheral artery
disease (PAD) that may damage the arterial wall, DABRA treats
blockages with minimal vascular trauma.
“DABRA quickly, safely, and efficiently restores blood flow,
often in very difficult cases, enabling physicians to save
patients’ limbs and lives,” added Dean Irwin, CEO, Ra Medical
Systems.
For more information, please visit Ra Medical Systems at
Booth No. 106 at NCVH or go to www.ramed.com. Each year, the
NCVH annual conference assembles over 1,500 attendees and features
live case transmissions, scientific lectures and faculty who are
considered preeminent in the field of medicine.
About Ra Medical Systems
Ra Medical Systems is a commercial medical device company
developing and marketing innovative excimer laser systems for the
treatment of vascular and dermatologic diseases. DABRA launched in
2017 for the endovascular treatment of blockages resulting from
lower extremity vascular disease and is CE marked for the
indication of the endovascular treatment of infrainguinal arteries
via atherectomy, and for crossing total occlusions. Pharos launched
in 2004 for the treatment of dermatological disorders including
psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos are
based on Ra Medical’s core excimer laser technology platform that
produces 308 nanometer light, a UVB wavelength that studies have
demonstrated increases T-cell apoptosis, or cell death, which may
produce a beneficial, targeted immunosuppressive effect. Ra Medical
manufactures DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is
licensed by the state of California to manufacture sterile,
single-use catheters in controlled environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical's future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as "may," "will," "should," "expects," "plans,"
"anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these words or other similar terms or
expressions that concern Ra Medical's future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential benefits to patients and physicians using the DABRA
catheter and laser system. Ra Medical's expectations and beliefs
regarding these matters may not materialize, and actual results in
future periods are subject to risks and uncertainties that could
cause actual results to differ materially from those projected or
implied by such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of DABRA and Pharos and procedures performed using such devices by
physicians, payors, and other third parties; development and
acceptance of new products or product enhancements; clinical and
statistical verification of the benefits achieved via the use of Ra
Medical’s products; the Company’s ability to effectually manage
inventory; Ra Medical’s ability to recruit and retain management
and key personnel; Ra Medical’s need to comply with complex and
evolving laws and regulations; intense and increasing competition
and consolidation in Ra Medical’s industry; the impact of rapid
technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory
inspections; and the other risks and uncertainties described in Ra
Medical’s news releases and filings with the Securities and
Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical's
business and operating results is contained in Ra Medical’s
Quarterly Report on Form 10-Q for the quarter March 31, 2019 and in
its other filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based on
information available to Ra Medical as of the date hereof, and Ra
Medical disclaims any obligation to update any forward-looking
statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings, and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190530005272/en/
Media ContactsCaitlin Kasunich / Lisa LipsonKCSA
Strategic Communications212.896.1241 /
508.843.6428ckasunich@kcsa.com / llipson@kcsa.com
Investor ContactJeffrey KrawsPresident, Ra Medical
Systems760.707.7516investorrelations@ramed.com
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Apr 2024 to May 2024
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From May 2023 to May 2024